2024
Clinical outcomes of SARS‐CoV‐2 infection in kidney transplant recipients on belatacept: a single‐center experience
Feller F, Azar M, Marvin J, Cohen E, Virmani S, Malinis M. Clinical outcomes of SARS‐CoV‐2 infection in kidney transplant recipients on belatacept: a single‐center experience. Transplant Infectious Disease 2024, 26: e14253. PMID: 38351494, DOI: 10.1111/tid.14253.Peer-Reviewed Original ResearchThe respiratory syncytial virus vaccines are here: Implications for solid organ transplantation
Trubin P, Azar M, Kotton C. The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation. American Journal Of Transplantation 2024, 24: 897-904. PMID: 38341028, DOI: 10.1016/j.ajt.2024.02.003.Peer-Reviewed Original ResearchRespiratory syncytial virusSolid organ transplantationLower respiratory tract diseaseHigh risk of infectious complicationsBurden of RSV diseaseOrgan transplantationRisk of infectious complicationsRespiratory syncytial virus vaccineRespiratory tract diseaseCenters for Disease Control and Prevention's Advisory CommitteeOrgan transplant recipientsSolid organ recipientsPoor clinical outcomesFood and Drug AdministrationRSV F glycoproteinRespiratory virus vaccinesRSV diseaseInfectious complicationsTransplant recipientsClinical outcomesSyncytial virusClinical decision-makingImmunocompromised individualsOrgan recipientsImmunization PracticesClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesDiagnosing peritoneal tuberculosis
Koff A, Azar MM. Diagnosing peritoneal tuberculosis. BMJ Case Reports 2020, 13: e233131. PMID: 32033999, PMCID: PMC7035809, DOI: 10.1136/bcr-2019-233131.Peer-Reviewed Original ResearchConceptsPeritoneal tuberculosisEmpiric anti-tuberculous therapyPositive QuantiFERON-TB GoldAnti-tuberculous therapyPresence of ascitesQuantiFERON-TB GoldWorse clinical outcomesLow-incidence regionsAscitic adenosine deaminaseInflammatory ascitesPeritoneal thickeningAbdominal painDecompensated cirrhosisLiver transplantationExtrapulmonary tuberculosisRadiographic responseAntibiotic therapyClinical outcomesTuberculosisIncidence regionDiagnosisMycobacterial testingItalian malesAdenosine deaminaseCirrhosisEmerging Microbiology Diagnostics for Transplant Infections: On the Cusp of a Paradigm Shift.
Azar MM, Gaston DC, Kotton CN, Malinis MF. Emerging Microbiology Diagnostics for Transplant Infections: On the Cusp of a Paradigm Shift. Transplantation 2020, 104: 1358-1384. PMID: 31972701, DOI: 10.1097/tp.0000000000003123.BooksConceptsHematopoietic stem cell transplantationInfected transplant recipientsInfectious disease specialistsStem cell transplantationBlood culture specimensArray of pathogensTransplant recipientsTransplant cliniciansClinical outcomesDisease specialistsCell transplantationTransplant infectionsMagnetic resonance-based methodsMicrobiology diagnosticsSolid organsCulture specimensMolecular testingMolecular panelResistance determinantsInfectionOutcomesDiagnostic microbiologyResonance-based methodsPatientsTransplantation
2016
Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs